TM Owner Pfizer
Oxbryta 500mg Tablet
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Oxbryta (voxelotor) 500 mg tablets have been voluntarily withdrawn from every market worldwide by the manufacturer, Pfizer, since 25 September 2024, and Oxbryta must no longer be prescribed, dispensed, or started in any patient.
- Before this withdrawal, Oxbryta was a haemoglobin-polymerisation inhibitor approved in the United States for sickle cell disease in adults and children aged 4 years and older, and in the European Union, from February 2022, for patients aged 12 years and older; it was taken by mouth, once daily, to reduce red blood cell sickling.
- Pfizer withdrew it after clinical trial and real-world data showed more deaths and more painful vaso-occlusive crises in patients taking voxelotor than in those on placebo, so its risks were judged to outweigh its benefits.
- Anyone still listed as taking this product should contact their sickle cell care team about alternative treatment.
Side Effects
- While marketed, Oxbryta's most commonly reported side effects were headache, diarrhoea, abdominal pain, nausea, fatigue, rash, hives and fever.
- The reason for its 2024 global withdrawal was more serious: post-marketing studies found a higher rate of vaso-occlusive (painful sickle cell) crises and more deaths among patients taking voxelotor than among those on placebo, findings serious enough that Pfizer and regulators judged the overall balance of risk to be unfavourable.
- A separate safety concern applies to anyone currently stopping the drug: sickle cell specialists have reported that abruptly stopping voxelotor can trigger a rebound surge in red-cell breakdown (haemolysis) and worsening sickle cell symptoms within days, sometimes needing hospital care.
- Anyone still taking Oxbryta should not simply stop it alone — contact the prescribing team urgently to plan a supervised transition, and seek immediate care for new jaundice, dark urine, or severe pain.
Precautions & Warnings
- Oxbryta is no longer available to start or continue in any country; this information is provided only to help patients transitioning off treatment.
- No boxed warning was in place on the US label during marketing; the withdrawal was a voluntary manufacturer decision following an unfavourable benefit-risk finding in ongoing trials, not a recall of individual batches for a manufacturing or contamination fault.
- It was taken orally, with or without food, usually once daily, and was never given by injection or infusion.
- Anyone still holding tablets should not restart or share them, and should discuss safe disposal with a pharmacist.
- Because sudden discontinuation can trigger a rapid rise in haemolysis, do not stop Oxbryta without first arranging a supervised transition plan and closer monitoring (blood counts, signs of jaundice) with the sickle cell care team, particularly in the days immediately after the last dose.
Avoid Interactions
- Because Oxbryta has been withdrawn worldwide, no new interacting medicines should be started specifically to work alongside it.
- If you have only recently stopped Oxbryta, continue to tell every healthcare provider, including any new sickle cell specialist, about all prescription and over-the-counter medicines, supplements and herbal products you use, since your overall treatment plan is being changed.
- Do not resume Oxbryta alongside any other sickle cell medicine without specific instruction from your care team, and do not obtain Oxbryta from any informal source once your local pharmacy supply has ended, since withdrawn stock is no longer covered by ordinary quality and safety monitoring.
- Bring your remaining tablets, or a note of the strength and dates you last took them, to every appointment while your new treatment is being planned.
References
Frequently Asked Questions
Oxbryta (voxelotor) was a tablet for sickle cell disease in adults and children 4 and older. Pfizer withdrew it worldwide on 25 September 2024 after trials showed more deaths and painful crises than placebo. It can no longer be prescribed or started.
Pfizer withdrew Oxbryta worldwide because later studies found higher death rates and more vaso-occlusive (painful sickle cell) crises in patients taking voxelotor than in those on placebo. Regulators, including the FDA and EMA, agreed the risks now outweighed the benefits for patients.
While marketed, Oxbryta commonly caused headache, diarrhoea, abdominal pain, nausea, fatigue, rash, hives and fever. The more serious concern that ultimately led to its withdrawal was an increased risk of vaso-occlusive crises and death, seen only in longer-term post-marketing safety data.
No. Stopping voxelotor abruptly can trigger a rebound rise in red blood cell breakdown (haemolysis) and worsening sickle cell symptoms within days, sometimes needing hospital treatment. Contact your sickle cell team urgently to arrange a properly supervised switch to another therapy.
Do not restart Oxbryta yourself or share leftover tablets with anyone else, even another sickle cell patient. Speak to your pharmacist about safe disposal, and bring any remaining tablets, or a note of when you last took them, to your next appointment.
Your sickle cell specialist can discuss other approved options, such as hydroxyurea, L-glutamine, or crizanlizumab, depending on your disease severity, age, and treatment history. Do not choose a replacement treatment yourself without your care team's specific guidance and monitoring.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
